GLP-1 Access Leads the Week

This week's practical theme is access and risk measurement. Some readers may need to check whether a new medicine program changes their cost, while others may need to ask whether their care plan is measuring the risks that are easiest to miss.

The Medicare GLP-1 Bridge program began on July 1, 2026, as a temporary Centers for Medicare & Medicaid Services demonstration project that is scheduled to run through December 31, 2027. 1 The covered medicines include Foundayo, the oral orforglipron pill; Zepbound KwikPen, the weekly tirzepatide injection; and Wegovy, semaglutide in injection and pill forms. 1

GLP-1 receptor agonists are medicines that mimic a gut hormone involved in appetite, blood sugar, and digestion. The practical change is price access for eligible people: the program uses a flat $50 monthly copay, and KFF, a health policy research organization, estimated that about 3.8 million Medicare beneficiaries meet eligibility criteria. 1 The catch is that prior authorization is required, the $50 copay does not count toward the Part D deductible or the annual $2,100 out-of-pocket maximum, and the low-income subsidy cannot be used to reduce the $50 cost. 1

The eligibility tiers are based on body mass index, or BMI, plus medical risk. The summary lists three routes: BMI of at least 35; BMI of at least 30 plus heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI of at least 27 plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. 1 Peripheral artery disease, or PAD, means narrowed arteries that reduce blood flow to the legs and can raise the risk of pain, wounds, procedures, and amputation.

For patients, the next step is administrative as much as medical. Ask your clinician which diagnosis codes, weight history, prior treatments, and risk conditions your plan will need before a prescription can move forward.

Eli Lilly said in a June 8, 2026 press release that the company planned to submit Foundayo for type 2 diabetes to the U.S. Food and Drug Administration by the end of the second quarter. 7 By July 6, the FDA's 2026 novel drug approvals page listed Foundayo for obesity, with no type 2 diabetes indication. 8 HCPLive's July 3 FDA recap said a regulatory submission for a type 2 diabetes indication is now "anticipated later in 2026." 9

That does not change anyone's prescription today. It does change expectations. Patients waiting for an oral GLP-1 option for type 2 diabetes should not assume a near-term FDA review timeline until Lilly or the FDA announces an actual submission or decision.

Ask your diabetes clinician: "Should we make a plan based on medicines available now, and revisit Foundayo only after there is a formal type 2 diabetes update?"

A Cleveland Clinic study published July 1, 2026 in the Journal of the American Heart Association compared 2,133 matched pairs of adults with type 2 diabetes and PAD in the TriNetX database. 3 GLP-1 receptor agonist users had a 26% lower risk of death from any cause, 13% fewer hospitalizations, up to 48% fewer amputations, and about 36% fewer revascularization procedures than metformin-only users. 3 Revascularization means a procedure to restore blood flow.

The strongest signal appeared in people with severe PAD, also called chronic limb-threatening ischemia, and in people with BMI of at least 30. 3 The study did not find a significant difference in heart attack, stroke, or serious kidney events between groups, and the observational design means it cannot prove that GLP-1 treatment caused the better outcomes. 3

If you have type 2 diabetes and PAD, bring the study to a visit rather than changing medicine on your own. The useful question is whether your current plan addresses glucose, weight, cholesterol, blood pressure, smoking, walking capacity, foot checks, and circulation risk together.

The American Heart Association warned on July 1, 2026 that extreme heat is the leading weather-related cause of death in the United States. 10 Heat makes the heart work harder because the heart rate rises and blood vessels expand as the body tries to cool itself. 10 The AHA advice is practical: avoid outdoor activity between noon and 3 p.m., wear lightweight and light-colored clothing, drink water instead of alcohol or caffeine, and take breaks in shade or air conditioning. 10

Heat stroke is an emergency. The AHA lists body temperature above 103 degrees Fahrenheit, hot red dry skin, a rapid strong pulse, and confusion as warning signs that should prompt a 911 call. 10 If you take diuretics, blood pressure medicines, or medicines that affect hydration, ask whether your heat plan should include extra monitoring.

Inflammation was the other cardiovascular signal this week. The POSEIDON study enrolled 18,904 patients across 317 sites in 18 countries from 2023 to 2025 and found that about 40% of patients with atherosclerotic cardiovascular disease and chronic kidney disease had elevated hsCRP of at least 2 mg/L despite standard guideline-directed therapy. 4 Atherosclerotic cardiovascular disease means plaque-related disease in arteries; hsCRP is high-sensitivity C-reactive protein, a blood test that can reflect inflammation.

The same study found similar elevated hsCRP rates across heart failure subtypes: 38.8% in heart failure with preserved ejection fraction, 38.1% in mildly reduced ejection fraction, and 38.2% in reduced ejection fraction. 4 This does not mean every patient needs a new drug. It does mean some people who appear treated by standard measures may still have residual inflammatory risk worth discussing.

For people who vape, the AHA also published a June 29, 2026 review warning that e-cigarette aerosol can contain formaldehyde, heavy metals, synthetic cooling chemicals, sweeteners, and flavoring agents classified by the FDA as harmful or potentially harmful constituents. 11 The AHA review said nicotine can raise blood pressure and heart rate, narrow blood vessels, increase blood clotting, and contribute to PAD. 11

Ask your clinician: "Given my heart history, should we measure hsCRP, adjust my heat safety plan, or build a quit plan for nicotine?"

MASH means metabolic dysfunction-associated steatohepatitis, the inflammatory form of fatty liver disease that can lead to scarring. On July 2, 2026, a modified Delphi consensus study reported agreement among 23 MASH experts from 10 countries that noninvasive tests are the best way to assess MASH treatment effectiveness. 5 Eighty percent agreed that noninvasive tests should replace liver biopsy as the preferred way to measure treatment outcomes, and 95% agreed that reductions in liver stiffness measurement by VCTE or MRE indicate treatment response. 5

VCTE is vibration-controlled transient elastography, often known by the brand name FibroScan. It estimates liver stiffness without a biopsy. MRE is magnetic resonance elastography, an MRI-based stiffness test. The same panel endorsed a 30% change in liver stiffness measurement and a 0.5-point change in enhanced liver fibrosis score as clinically meaningful thresholds. 5

A Cleveland Clinic Journal of Medicine review published July 1, 2026 gives primary-care clinicians a stepwise approach: identify at-risk patients, calculate FIB-4, send people with FIB-4 of at least 1.3 to VCTE, and refer to hepatology when VCTE is at least 8 kPa. 6 FIB-4 is a score calculated from age, AST, ALT, and platelet count; AST and ALT are common liver enzymes on blood tests. The review also notes that FIB-4 is less reliable in adults under 35 and in patients with diabetes, so VCTE may be reasonable even when FIB-4 is below 1.3. 6

Real-world data make the monitoring question more urgent. In the TARGET-NASH cohort of 1,964 adults with MASH and at least F2 fibrosis, 17% of patients with F2 to F3 fibrosis progressed to cirrhosis in a median 16 months. 12 The same report noted that only 79% of patients had the lab values needed for FIB-4 calculation and 36% had FibroScan data. 12

Ask your clinician: "Do we have the blood tests needed to calculate FIB-4, and should I have VCTE or another liver stiffness test?"

A UK Biobank analysis published July 1, 2026 followed 354,957 participants without cirrhosis or liver cancer at enrollment for a median 13 years. 13 Compared with non-drinkers, people who drank at least 5 cups of coffee daily had 32% lower cirrhosis risk, 47% lower hepatocellular carcinoma risk, and 42% lower liver-related mortality. 13 Hepatocellular carcinoma is the most common type of primary liver cancer.

Both caffeinated and decaffeinated coffee showed similar associations, which suggests that compounds other than caffeine may contribute to the liver signal. 13 The study also reported that sugar or artificial sweeteners partially offset benefits, with sweetener users having 1.36 times the odds of an MRI marker linked to inflammation or fibrosis. 13

This is a conversation starter, not a treatment instruction. If coffee worsens reflux, anxiety, sleep, palpitations, or blood pressure, the liver signal may not outweigh those issues for you.

A U.S. Department of Veterans Affairs cohort study published July 6, 2026 included 98,076 people with MetALD, a condition involving both metabolic dysfunction and alcohol-associated liver disease. 14 Among them, 12,613 patients, or 12.9%, had lean MetALD, defined as BMI below 23 kg/m² for Asian patients or below 25 kg/m² for others. 14

Lean MetALD patients had an 82% higher adjusted risk of death from any cause than non-lean MetALD patients. 14 They also had higher hepatic decompensation rates, 7.2% versus 4.4%, and higher liver-related death rates, 0.9% versus 0.4%. 14 Hepatic decompensation means the liver has developed complications such as fluid buildup, bleeding risk, confusion from toxins, or jaundice.

The patient point is direct: a normal BMI should not end the liver-risk conversation when alcohol and abnormal liver tests are present. Ask, "Based on my liver tests, alcohol use, diabetes risk, and family history, do I need fibrosis screening even if my weight is normal?"

A BMJ Frontline Gastroenterology review in 2026 summarized patient-focused nutrition guidance for MASLD. 15 The review lists weight-loss targets of 5% to improve steatosis, 7% to 10% to improve steatohepatitis or fibrosis, and 3% to 5% for normal-weight individuals. 15 It also identifies the Mediterranean diet as the most recommended dietary pattern in international guidelines and emphasizes reducing commercially produced fructose, saturated fats, and ultra-processed foods while increasing dietary fiber, omega-3-rich foods, and coffee when appropriate. 15

That advice is easier to use when it becomes specific. Ask your clinician or dietitian: "What is one food swap I can make this week that fits my culture, budget, and liver goals?"